The 2026 China Pharmaceutical Innovation and Invention Index highlights the pharmaceutical companies and emerging innovators shaping the next phase of China’s rapidly evolving innovation ecosystem.
“Hengrui’s position at the forefront of this index – leading it for the second consecutive time – reflects genuine, evidence-based leadership in novel drug development with increasingly global scope and impact. This ranking is not simply a reflection of scale – it is a rigorous assessment of novel science and the ability to bring meaningful medicines to patients. We are proud to honor their achievement and see it as a signal of what China’s innovation ecosystem is capable of on the world stage.”
John Barry, Executive Vice President Corporate Development & Strategy at SAI
Download to report to learn:
- How China’s innovation leaders are increasingly combining R&D strength with commercial execution.
- Which emerging innovators will signal the next wave of Chinese innovation.
Download the full report here >>
